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Over the last 20 years, there have been remarkable advances in our understanding 
of pathogenic mechanisms in multiple sclerosis (MS), particularly those responsible 
for relapses and remissions. Over the same period a series of increasingly more 
effective treatments have become available that suppress relapses. However there 
has been a conspicuous lack of success treating progressive MS, which eventually 
affects most people with the condition, and is associated with the greatest disability. 
This has led to a reappraisal of pathological processes underlying progressive MS, 
and the recognition that pathology is more extensive and complicated than formerly 
thought.  
Previously, a commonly held view of MS was of a multi-focal and multi-phasic 
immune-mediated white matter inflammatory demyelinating disorder, and indeed the 
suppression of such a process has underpinned the major progress in disease 
modifying treatment to date. However, it is now abundantly clear that in progressive 
MS, demyelinating lesions may be as extensive in grey matter as they are in white 
matter, and that there is substantial and widespread neuro-axonal loss, not only in 
white matter lesions but also in normal-appearing white matter, and in both the 
cortical and deep grey matter. It is also clear that grey matter pathology is present in 
early relapsing-remitting MS and increases with time. Neuro-axonal loss is now 
thought to be responsible for a major proportion of irreversible progressive disability 
in MS, but its causes are poorly understood, particularly when it occurs in the grey 
matter.  
Brain atrophy in MS, as measured during life by MRI, is likely to reflect neuro-axonal 
loss (although other factors that can affect brain tissue volumes, especially when 
assessing short term changes, should be borne in mind). Loss of brain tissue does 
not occur uniformly, and in progressive MS it is most apparent in brain grey matter, 
affecting some cortical and deep grey matter regions more than others [Bendfelt et 
al., 2011]. In vivo MRI-clinical correlation studies have identified significant 
associations of grey matter atrophy with cognitive impairment, physical disability and 
progressive MS that are independent of associations with other imaging 
abnormalities, such as white matter lesion load. All-in-all, there are compelling 
reasons to try to better understand the mechanisms of grey matter atrophy and the 
neurodegeneration that it reflects. 
  
In this issue of Brain, Steenwijk and colleagues report on their work looking at 
patterns of cortical grey matter atrophy in MS. They used source-based 
morphometry (SBM), an evolution of the widely used voxel based morphometry 
(VBM) approach. Both SBM and VBM identify regional disease effects on MRI scans 
without first specifying where to look (Figure 1). However, whereas VBM looks for 
regions that are consistently different between groups, SBM looks for regions where 
MRI features tend to vary together, and then determines how these are weighted in 
different groups. In practical terms, this means that SBM may be more sensitive to 
distributed but connected regional disease effects, as occurs when a brain network is 
damaged. SBM has the potential to provide useful insight into the pathogenesis and 
pathophysiology of MS, but its interpretation is challenging, as exemplified by the 
present study. 
Consistent with previous VBM studies, the SBM analysis confirms that grey matter 
atrophy does not occur evenly throughout the cortex. However, it also shows that 
underlying this are overlapping regional ‘patterns’ of non-random cortical atrophy. 
The authors hypothesise that these atrophy patterns are initiated by the tract-
mediated effects of white matter lesions on cortical 'hubs' (cortical regions centrally 
located in structural networks), with subsequent network-mediated (trans-synaptic) 
degeneration then extending from these hubs. Previous studies support such a 
network-based interpretation [Calabrese et al., 2015], but do not necessarily exclude 
alternative explanations (Table 1). The tract-mediated effects of white matter lesions 
may themselves directly result in non-random cortical changes: lesions preferentially 
accrue in certain white matter regions [Brownell and Hughes, 1962], axonal 
transection will be more likely in tracts traversing these regions, and so cortical 
neurodegeneration (and atrophy) due to secondary anterograde or retrograde 
degeneration will be greater in regions connected with these tracts.  
Other mechanisms that may contribute to non-random grey matter 
neurodegeneration (and by implication cortical atrophy) need not be mediated at all 
via network or white matter tract degeneration. Meningeal inflammation, targeted 
grey matter immune processes, and regional metabolic vulnerability could all 
plausibly cause non-random regional neuronal loss and atrophy (Table 1). It is also 
possible that multiple mechanisms are at work, resulting in multiple patterns of non-
random cortical atrophy. 
The Steenwijk study also demonstrates that the relationship between cortical 
pathology and neurological impairments is not straightforward. Of the ten cortical 
thickness patterns found, four were independently linked with variations in EDSS 
scores, but only one of these was significantly associated with MS. This raises the 
possibility that natural variation in cortical networks may also significantly influence 
clinical outcomes in people with MS. This concept is not without precedence, for 
example there is already evidence that people with a higher maximal lifetime brain 
growth are relatively protected against the cognitive deficits in MS [Sumowski et al., 
2014]. 
Having shown that there are multiple spatial patterns underlying cortical grey matter 
atrophy in MS, we now need to determine what lies beneath them. Pursuing a 
structural network-mediated hypothesis, in the present study whole brain white 
matter measures explained at most 20% of the variation in cortical thickness patterns 
([Steenwijk et al., 2015], Table 3). However, as the authors point out, this may under-
  
estimate the true association as tract-specific links may be diluted in the global white 
matter measures employed by the study. A pattern-by-pattern analysis of cortical 
regions and the white matter tracts that connect them would be informative. Being a 
single time-point study, Steenwijk and colleagues were also not able to investigate 
the temporal relationship of abnormalities within a network or between regional grey 
matter and their associated white matter tracts. Longitudinal studies with similar 
types of regional analysis could elucidate the sequence of events, and provide 
evidence for abnormalities that are causal and others that are consequential. Indeed, 
a recent study in primary progressive MS reports white matter tract abnormalities 
preceding changes in tissue integrity in anatomically linked grey matter (assessed 
with magnetisation transfer ratio measures; [Bodini et al., 2015]), which would be 
consistent with at least some of the grey matter pathology in this form of MS being 
secondary to white matter tract degeneration.  
In summary, Steenwijk and colleagues have identified an important new feature of 
MS cortical grey matter atrophy: that it not only occurs in some cortical regions more 
than others but also that regions of predilection can be linked in a non-random way. 
There could be several explanations for these findings, and elucidation of these 
would be worthwhile given the clinical importance of grey matter atrophy in MS, and 
the potential to find new mechanisms for rationally based therapies that aim to 
prevent this striking neurodegenerative aspect of the disease. 
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Table 1: Potential mechanisms of non-random regional cortical neuro-degeneration 
(and by implication cortical atrophy) in multiple sclerosis 
Mechanism Description 
Network mediated 
It has been shown that structural changes occur in the 
occipital cortex after optic neuritis, consistent with trans-
synaptic neurodegeneration [Audoin et al. 2006]. Trans-
synaptic degeneration in brain networks could lead to 
non-random patterns of cortical atrophy. 
Axonal transection in 
white matter tracts 
Axonal transection is common in acute inflammatory 
demyelinating white matter lesions [Calabrese et al. 
,2015]. White matter lesions tend to accrue in watershed 
regions (for example around the lateral ventricles) 
[Brownell & Hughes, 1962] and so their tract-mediated 
effects on cortical grey matter (secondary 
neurodegeneration and atrophy) will be not be random. 
Meningeal lymphoid-
like aggregates 
Lymphoid-like meningeal aggregates occur particularly in 
progressive MS [Magliozzi et al., 2006], are associated 
with cortical neurodegeneration and subpial cortical 
demyelination [Magliozzi et al., 2006 and 2010], and are 
located mainly in the cingulate gyrus, temporobasal and 
frontobasal cortices [Kutzelnigg et al. ,2006]; it is 
plausible that they could cause non-random regional 
cortical atrophy. 
Targeted immune 
processes 
CD8+ T cells are seen in MS cortical lesions, and have 
been linked with neuronal damage. MHC I expression 
differs between neuronal sub-populations [Calabrese et 
al., 2015], and so may result in non-random 
neurodegeneration and atrophy. Antigenic differences 
between neuronal sub-populations may also result in 
non-random regional effects. 
Metabolic 
vulnerability 
In more classical neurodegenerative conditions, such as 
Alzheimer’s disease, regional differences in the tolerance 
of neuronal sub-populations to metabolic stress has been 
proposed as a cause of non-random cortical neuronal 
loss and atrophy [Saxena and Caroni, 2011]; such an 
effect might also operate with metabolic stress that 
occurs in MS [Witte et al., 2014]. 
 
 
 
  
 
 
Figure 1: Comparison of source and voxel based morphometry 
Left: Overlying pathological patterns combine with normal anatomy to produce the 
observed magnetic resonance images (MRI). Middle: Voxel based morphometry  
(VBM) assesses where there are regionally consistent differences in MRIs between 
groups that exceed a predefined threshold (regions in red on the VBM map). Right: 
Source based morphometry (SBM) first identifies regional patterns where tissue 
features are related (coloured regions on the SBM map), and then determines how 
these differ between groups. 
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